|

Agenda-staging

The Live Virtual Experience will include top experts sharing highlights from over 25 on-demand presentations*, available 9 September 2021. The on-demand presentations will be available through the virtual platform. These interactive panel discussions will also feature debates and Q&A from the live audience.

= On-Demand Presentation
 
= Live Presentation
 

Friday 17 September 2021

Day 1
9:00 AM (EDT)
15:00 (GMT +2) (CEST)		 5 mins

Opening Remarks

 Tadeusz Robak, MD, PhD
    Theme 1: Pathogenesis of CLL  
9:05 AM (EDT)
15:05 (GMT +2) (CEST)		 5 mins Session 1: Molecular Pathogenesis
of CLL – Genomics and Proteomics

 Co-Chairs: Catherine J. Wu, MD
& Clare Sun, MD
   

Genomic Analysis of CLL
On-Demand Presentation

 Anna Schuh, MD, PhD
   

Novel Insights From
Proteogenomic Analysis
On-Demand Presentation

 Michael Gillette, MD, PhD
9:10 AM (EDT)
15:10 (GMT +2) (CEST)		 30 mins Panel Discussion featuring highlights from the
following on-demand presentations:
*Genomic Analysis of CLL &
*Novel Insights From Proteogenomic Analysis
 Catherine J. Wu, MD; Clare Sun, MD; Anna Schuh, MD, PhD; Michael Gillette, MD, PhD
9:40 AM (EDT)
15:40 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
9:50 AM (EDT)
15:50 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
10:00 AM (EDT)
16:00 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
10:05 AM (EDT)
16:05 (GMT +2) (CEST)		 5 mins Session 2: Molecular Pathogenesis of CLL – Microenvironment & Signaling

 Co-Chairs: Nicholas Chiorazzi, MD
& Sarka Pospisilova, PhD
   

Trafficking of CLL Cells To and From the Microenvironmental Niche
On-Demand Presentation

 

 Andrea Pepper, PhD
    Effects of Distinct Receptor-Ligand Systems
(BCR, TLR, Chemokine Receptors) in the Survival
and Growth of CLL Cells
On-Demand Presentation

 Dimitar Efremov, MD, PhD
    Crosstalk of Microenvironmental Elements
in the Tissue Microenvironment
On-Demand Presentation

 Alan Ramsay, PhD
10:10 AM (EDT)
16:10 (GMT +2) (CEST)		 36 mins Panel Discussion featuring highlights
from the following on-demand presentations:
*Trafficking of CLL Cells To and From
the Microenvironmental Niche
*Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells
*Crosstalk of Microenvironment Elements in the Tissue Microenvironment
 Nicholas Chiorazzi, MD; Sarka Pospisilova, PhD; Andrea  Pepper, PhD; Dimitar Efremov, MD, PhD; Alan Ramsay, PhD
10:46 AM (EDT)
16:46 (GMT +2) (CEST)		 7 mins Live Oral Abstract
  
10:53 AM (EDT)
16:53 (GMT +2) (CEST)		 7 mins Live Oral Abstract
  
11:00 AM (EDT)
17:00 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
11:05 AM (EDT)
17:05 (GMT +2) (CEST)		 5 mins

Session 3: Clonal Dynamics, Competition,
and Disease Evolution

 Co-Chairs: Gianluca Gaidano, MD, PhD
& Adalgisa Condoluci, MD
    Mechanisms of Epigenetic Dynamics/Evolution
On-Demand Presentation

 Davide Rossi, MD, PhD
    Perspectives of Clonal Evolution at the
Single-Cell Level
On-Demand Presentation

 Catherine J. Wu, MD
11:10 AM (EDT)
17:10 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
11:20 AM (EDT)
17:20 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
11:30 AM (EDT)
17:30 (GMT +2) (CEST)		 30 mins Panel Discussion featuring highlights
from the following
on-demand presentations:
*Mechanisms of Epigenetic Dynamics/Evolution
*Perspectives of Clonal Evolution at the Single-Cell Level
 Gianluca Gaidano, MD, PhD; Adalgisa Condoluci, MD; Davide Rossi, MD, PhD; Catherine J. Wu, MD
12:00 PM (EDT)
18:00 (GMT +2) (CEST)		   End of Day 1  
12:00 PM (EDT)
18:00 (GMT +2) (CEST)		 60 mins Poster Session  
1:00 PM (EDT)
19:00 (GMT +2) (CEST)		   Poster Session Concludes  

Saturday 18 September 2021

Day 2
    Theme 2: Approach Considerations and Treatment Options in CLL  
9:00 AM (EDT)
15:00 (GMT +2) (CEST)		 5 mins Opening Remarks & Recap of Previous Day

Kostas Stamatopoulos, MD, PhD
9:05 AM (EDT)
15:05 (GMT +2) (CEST)		 5 mins Session 4: Prognostication and Prediction in the
Era of Novel Drugs

 Chair: Peter Hillmen, MB ChB, PhD
    The Use of Conventional Prognostic Markers with Targeted Therapy
On-Demand Presentation

 Eugen Tausch, MD
    Genomic Profiling and Treatment Decisions
in the Non-Chemotherapy Era
On-Demand Presentation

 Romain Guièze, MD
9:10 AM (EDT)
15:10 (GMT +2) (CEST)		 45 mins Panel Discussion featuring highlights from the
following on-demand presentations:
*The Use of Conventional Prognostic Markers with
Targeted Therapy
*Genomic Profiling and Treatment Decisions in the
Non-Chemotherapy Era
 Peter Hillmen, MB ChB, PhD; Eugen Tausch, MD; Romain Guièze, MD
9:55 AM (EDT)
15:55 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
10:05 AM (EDT)
16:05 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
10:15AM (EDT)
16:15 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
10:20 AM (EDT)
16:20 (GMT +2) (CEST)		 5 mins Session 5: Minimal Residual Disease – Methods and Clinical Application

 Co-Chairs: Thomas Kipps, MD, PhD
& Kirsten Fischer, MD
    Minimal Residual Disease
On-Demand Presentation

 William Wierda, MD, PhD
10:25 AM (EDT)
16:25 (GMT +2) (CEST)		 20 mins

Debate: To MRD or Not to MRD –
Can We Use MRD to Direct Standard Practice?

Moderator:  Thomas Kipps, MD, PhD

Debaters:
Peter Hillmen,MB, ChB, PhD;
John Burke, MD
10:45 AM (EDT)
16:45 (GMT +2) (CEST)		 25 mins Panel Discussion featuring highlights from
the following on-demand presentations:
*Minimal Residual Disease
 Thomas Kipps, MD, PhD; Kirsten Fischer, MD; William Wierda, MD, PhD
11:10 AM (EDT)
17:10 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
11:20 AM (EDT)
17:20 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
11:30 AM (EDT)
17:30 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
11:35 AM (EDT)
17:35 (GMT +2) (CEST)		 60 mins Industry Supported Satellite Symposia  
12:35 PM (EDT)
18:35 (GMT +2) (CEST)		 10 mins Binet/Rai Medal Presentation
  
12:45 PM (EDT)
18:45 (GMT +2) (CEST)		 5 mins Session 6: Front-Line Therapy of CLL

 Co-Chairs: Barbara Eichhorst, MD
& Lydia Scarfo, MD
    Relevant Factors for Choice of Frontline Therapy
On-Demand Presentation

 Arnon Kater, MD, PhD
    Treatment of Very High Risk CLL
(TP53, Complex Karyotype; IGHV Subset 2)
On-Demand Presentation

 Inhye Ahn, MD
    Chemotherapy in the Front Line Setting:
Is it Still Useful in Combination with
Newer Substances?
On-Demand Presentation

 Matthew Davids, MD, MMSc
12:50 PM (EDT)
18:50 (GMT +2) (CEST)		 30 mins Panel Discussion featuring highlights from
the following on-demand presentations:
*Relevant Factors for Choice of Frontline Therapy
*Treatment of Very High Risk CLL (TP53, Complex
Karyotype; IGHV Subset 2)
*Chemotherapy in the Front Line Setting: Is it
Still Useful in Combination with Newer Substances?
 Barbara Eichhorst, MD; Lydia Scarfo, MD; Arnon Kater, MD, PhD; Inhye Ahn, MD; Matthew Davids, MD, MMSc
1:20 PM (EDT)
19:20 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
1:30 PM (EDT)
19:30 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
1:40 PM (EDT)
19:40 (GMT +2) (CEST)		   End of Day 2  
1:40 PM (EDT)
19:40 (GMT +2) (CEST)		 60 mins Poster Session  
2:40 PM (EDT)
20:40 (GMT +2) (CEST)		   Poster Session Concludes  

Sunday 19 September 2021

Day 3
9:00 AM (EDT)
15:00 (GMT +2) (CEST)		 5 mins Opening Remarks & Recap of Previous Day

Jan Burger, MD, PhD
9:05 AM (EDT)
15:05 (GMT +2) (CEST)		 5 mins Session 7: Treatment of Relapsed/Refractory CLL

 Co-Chairs: John Seymour, MD
& Meghan Thompson, MD
    Resistance to Venetoclax: Mechanisms,
Risk Factors and Preventative Strategies
On-Demand Presentation

 Andrew Roberts, MBBS, PhD
    A Clinical Perspective on Resistance
to Covalent BTKi
On-Demand Presentation

 Jennifer Woyach, MD
    Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient
On-Demand Presentation

 Richard Rosenquist, MD, PhD
9:10 AM (EDT)
15:10 (GMT +2) (CEST)		 30 mins Panel Discussion featuring highlights from
the following on-demand presentations:
*Resistance to Venetoclax: Mechanisms, Risk Factors,
and Preventative Strategies
*A Clinical Perspective on Resistance to Covalent BTKi
*Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient
 John Seymour, MD; Meghan Thompson, MD; Andrew Roberts, MBBS, PhD;
Jennifer Woyach, MD; Richard Rosenquist, MD, PhD
9:40 AM (EDT)
15:40 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
9:50 AM (EDT)
15:50 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
10:00AM (EDT)
16:00 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
    Theme 3: Rationally Designed Therapy on the
Horizon in CLL 		 
10:05 AM (EDT)
16:05 (GMT +2) (CEST)		 5 mins Session 8: New Agents in CLL Clinical Trials

 Co-Chairs: Jennifer Woyach, MD
& Lindsey Roeker, MD
    Refining our Standard Approaches
On-Demand Presentation

 Paolo Ghia, MD, PhD
    Reversible BTK Inhibitors
On-Demand Presentation

 Jennifer Brown, MD, PhD
    Preclinical Methods for Drug Discovery
On-Demand Presentation

 Rosa Lapalombella, PhD
10:10 AM (EDT)
16:10 (GMT +2) (CEST)		 30 mins Panel Discussion featuring highlights from
the following on-demand presentations:
*Refining our Standard Approaches
*Reversible BTK Inhibitors
*Preclinical Methods for Drug Discovery
 Jennifer Woyach, MD; Lindsey Roeker, MD; Paolo Ghia, MD, PhD; Jennifer Brown, MD, PhD; Rosa Lapalombella, PhD
10:40 AM (EDT)
16:40 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
10:50 AM (EDT)
16:50 (GMT +2) (CEST)		 10 mins Live Oral Abstract
  
11:00 AM (EDT)
17:00 (GMT +2) (CEST)		 60 mins Industry Supported Satellite Symposia

  
12:00 AM (EDT)
18:00 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
12:05 PM (EDT)
18:05 (GMT +2) (CEST)		 5 mins Session 9: Immunotherapy of CLL

 Co-Chairs: John Gribben, MD, DSc
& David Maloney, MD, PhD
12:10 PM (EDT)
18:10 (GMT +2) (CEST)		 30 mins Debate – CAR T-cell Therapy vs Allo-SCT

Moderators: John Gribben, MD, DSc;

Debaters:
Jordan Gauthier MD, MSc; Peter Dreger, MD
   

T Cells in CLL Biology and Treatment: Friends or Foe?
On-Demand Presentation

 Jan Burger, MD, PhD
    Bispecific Monoclonal Antibodies
On-Demand Presentation

 Adrian Wiestner, MD, PhD
12:40 PM (EDT)
18:40 (GMT +2) (CEST)		 12 mins Live Oral Abstract
  
12:52 PM (EDT)
18:52 (GMT +2) (CEST)		 12 mins Live Oral Abstract
  
1:05 PM (EDT)
19:05 (GMT +2) (CEST)		 25 mins Panel Discussion featuring the following on-demand presentations:
*Bispecific Monoclonal Antibodies
*T Cells in CLL Biology and Treatment: Friends or Foe?

 John Gribben, MD, DSc
David Maloney, MD, PhD
Jan Burger, MD, PhD
Adrian Wiestner, MD, PhD
Jordan Gauthier MD, MSc
Peter Dreger, MD
1:30 PM (EDT)
19:30 (GMT +2) (CEST)		   End of Day 3  
1:30 PM (EDT)
19:30 (GMT +2) (CEST)		 60 mins Poster Session  
2:30 PM (EDT)
20:30 (GMT +2) (CEST)		   Poster Session Concludes  
2:45 PM (EDT)
20:45 (GMT +2) (CEST)		 60 mins Industry Supported Satellite Symposium  

Monday 20 September 2021

Day 4
9:00 AM (EDT)
15:00 (GMT +2) (CEST)		 5 mins Opening Remarks & Recap of Previous Day

Tamar Tadmor, MD
9:05 AM (EDT)
15:05 (GMT +2) (CEST)		 5 mins Session 10: Supportive Care and Consequences
of Immune Dysregulation in CLL

 Co-Chairs: Jennifer Brown, MD, PhD
& Jackie Barrientos, MD
    Infection Risk in CLL
On-Demand Presentation

 Carsten Niemann, MD, PhD
    Infection Risk with Novel Agents
On-Demand Presentation

 Florence Cymbalista, MD, PhD
    COVID-19 and CLL
On-Demand Presentation

 Lydia Scarfò, MD
    Management of Autoimmune Cytopenias in
the Era of Targeted Agents
On-Demand Presentation

 Kerry Rogers, MD
    Management of Cardiac Complications
of BTK Inhibitors
On-Demand Presentation

 Javid Moslehi, MD
9:10 AM (EDT)
15:05 (GMT +2) (CEST)		 5 mins Live Oral Abstract
  
9:15 AM (EDT)
15:15 (GMT +2) (CEST)		 5 mins Live Oral Abstract
  
9:20 AM (EDT)
15:20 (GMT +2) (CEST)		 35 mins Panel Discussion featuring the
following on-demand presentations:
*Infection Risk in CLL
*Infection Risk with Novel Agents
*COVID-19 and CLL
*Management of Autoimmune Cytopenias in the Era of Targeted Agents
*Management of Cardiac Complications of BTK Inhibitors
 Jennifer Brown, MD, PhD; Jackie Barrientos, MD; Carsten Niemann, MD, PhD; Florence Cymbalista, MD, PhD; Kerry Rogers, MD; Lydia Scarfò, MD; Javid Moslehi, MD
9:55 AM (EDT)
15:55 (GMT +2) (CEST)		 60 mins Industry Supported Satellite Symposia  
10:55 AM (EDT)
16:55 (GMT +2) (CEST)		 5 mins Visit Exhibit Hall & Break  
    Theme 4: From Global Perspectives to Patient Experiences – How iwCLL Is Leading the Way  
11:00 AM (EDT)
17:00 (GMT +2) (CEST)		 5 mins Session 11: Real-World Data and Patient Experiences

 Co-chairs: Peter Hillmen, MB ChB, PhD; John Seymour, MD
11:05 AM (EDT)
17:10 (GMT +2) (CEST)		 10 mins The iwCLL Global Partnerships Sub-Committee Update
 Anna Schuh, MD, PhD
11:15 AM (EDT)
17:15 (GMT +2) (CEST)		 7 mins ERIC Updates
 Paolo Ghia, MD, PhD
11:22 AM (EDT)
17:22 (GMT +2) (CEST)		 7 mins Update on Geographic Diversity
and Management of CLL in China
 Shenmiao Yang, MD
11:29 AM (EDT)
17:29 (GMT +2) (CEST)		 7 mins Update on Geographic Diversity
and Management of CLL in South America
 Carlos Sergio Chiattone, MD, MSc, PhD
11:36 AM (EDT)
17:36 (GMT +2) (CEST)		 7 mins Update on Geographic Diversity
and Management of CLL in Africa
 Clara Chamba, MD
11:43 AM (EDT)
17:43 (GMT +2) (CEST)		 5 mins Live Oral Abstract
  
11:48 AM (EDT)
17:48 (GMT +2) (CEST)		 5 mins Live Oral Abstract
  
11:53 AM (EDT)
17:53 (GMT +2) (CEST)		 15 mins Real-World Data Roundtable Discussion
 Peter Hillmen, MB ChB, PhD
Anna Schuh, MD
Paolo Ghia, MD, PhD
Shenmiao Yang, MD
Carlos Sergio Chiattone, MD, MSc, PhD
Clara Chamba, MD
12:08 PM (EDT)
18:08 (GMT +2) (CEST)		 7 mins Visit Exhibit Hall & Break  
12:15 PM (EDT)
18:15 (GMT +2) (CEST)		   Session 11: Real-World Data and Patient
Experiences (Part 2)		  
12:15 PM (EDT)
18:15 (GMT +2) (CEST)		 45 mins Live Panel Discussion:
Spotlight on the CLL Patient Experience: Perspectives Learned From Three Datasets & Patient Experience/Perspective/Solutions
 John Seymour, MD; Deborah Sims; Dr. Brian Koffman, CMO and EVP, CLL Society; Lorna Warwick, CEO, Lymphoma Coalition; Zack Pemberton-Whiteley, CEO, Leukaemia Care
1:00 PM (EDT)
19:00 (GMT +2) (CEST)		 5 mins Session 12: Looking to the Future of CLL and iwCLL Michael Hallek, MD, PhD; Peter Hillmen, MB ChB, PhD
1:05 PM (EDT)
19:05 (GMT +2) (CEST)		 30 mins Keynote: Advances in CLL: Is It Time to Talk Cure?
 Michael Hallek, MD, PhD
1:35 PM (EDT)
19:35 (GMT +2) (CEST)		 15 mins iwCLL Updates and iwCLL 2023
 Peter Hillmen, MB ChB, PhD; Jennifer Brown, MD, PhD
1:50 PM (EDT)
19:50 (GMT +2) (CEST)		 5 mins Closing Comments
 Michael Hallek, MD, PhD
1:55 PM (EDT)
19:55 (GMT +2) (CEST)		   Close of Workshop